200 related articles for article (PubMed ID: 21385944)
1. N-naphthoyl-beta-naltrexamine (NNTA), a highly selective and potent activator of μ/kappa-opioid heteromers.
Yekkirala AS; Lunzer MM; McCurdy CR; Powers MD; Kalyuzhny AE; Roerig SC; Portoghese PS
Proc Natl Acad Sci U S A; 2011 Mar; 108(12):5098-103. PubMed ID: 21385944
[TBL] [Abstract][Full Text] [Related]
2. Opioid activity of spinally selective analogues of N-naphthoyl-β-naltrexamine in HEK-293 cells and mice.
Le Naour M; Lunzer MM; Powers MD; Portoghese PS
J Med Chem; 2012 Jan; 55(2):670-7. PubMed ID: 22136373
[TBL] [Abstract][Full Text] [Related]
3. Putative kappa opioid heteromers as targets for developing analgesics free of adverse effects.
Le Naour M; Lunzer MM; Powers MD; Kalyuzhny AE; Benneyworth MA; Thomas MJ; Portoghese PS
J Med Chem; 2014 Aug; 57(15):6383-92. PubMed ID: 24978316
[TBL] [Abstract][Full Text] [Related]
4. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities.
Healy JR; Bezawada P; Shim J; Jones JW; Kane MA; MacKerell AD; Coop A; Matsumoto RR
ACS Chem Neurosci; 2013 Sep; 4(9):1256-66. PubMed ID: 23713721
[TBL] [Abstract][Full Text] [Related]
6. Clinically employed opioid analgesics produce antinociception via μ-δ opioid receptor heteromers in Rhesus monkeys.
Yekkirala AS; Banks ML; Lunzer MM; Negus SS; Rice KC; Portoghese PS
ACS Chem Neurosci; 2012 Sep; 3(9):720-7. PubMed ID: 23019498
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
8. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M
Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171
[TBL] [Abstract][Full Text] [Related]
9. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
[TBL] [Abstract][Full Text] [Related]
10. Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception.
Stevenson GW; Folk JE; Linsenmayer DC; Rice KC; Negus SS
J Pharmacol Exp Ther; 2003 Dec; 307(3):1054-64. PubMed ID: 14557380
[TBL] [Abstract][Full Text] [Related]
11. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series.
Daniels DJ; Lenard NR; Etienne CL; Law PY; Roerig SC; Portoghese PS
Proc Natl Acad Sci U S A; 2005 Dec; 102(52):19208-13. PubMed ID: 16365317
[TBL] [Abstract][Full Text] [Related]
12. Activity of the delta-opioid receptor is partially reduced, whereas activity of the kappa-receptor is maintained in mice lacking the mu-receptor.
Matthes HW; Smadja C; Valverde O; Vonesch JL; Foutz AS; Boudinot E; Denavit-Saubié M; Severini C; Negri L; Roques BP; Maldonado R; Kieffer BL
J Neurosci; 1998 Sep; 18(18):7285-95. PubMed ID: 9736649
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological Characterization of Dezocine, a Potent Analgesic Acting as a κ Partial Agonist and μ Partial Agonist.
Wang YH; Chai JR; Xu XJ; Ye RF; Zan GY; Liu GY; Long JD; Ma Y; Huang X; Xiao ZC; Dong H; Wang YJ
Sci Rep; 2018 Sep; 8(1):14087. PubMed ID: 30237513
[TBL] [Abstract][Full Text] [Related]
14. Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice.
Ide S; Minami M; Satoh M; Uhl GR; Sora I; Ikeda K
Neuropsychopharmacology; 2004 Sep; 29(9):1656-63. PubMed ID: 15100703
[TBL] [Abstract][Full Text] [Related]
15. N-cyclobutylmethyl analog of normorphinone, N-CBM-TAMO: a short-term opioid agonist and long-term Mu-selective irreversible opioid antagonist.
Xu JY; Seyed-Mozaffari A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1996 Nov; 279(2):539-47. PubMed ID: 8930155
[TBL] [Abstract][Full Text] [Related]
16. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
Qi JA; Heyman JS; Sheldon RJ; Koslo RJ; Porreca F
J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
[TBL] [Abstract][Full Text] [Related]
17. Central antinociception induced by ketamine is mediated by endogenous opioids and μ- and δ-opioid receptors.
Pacheco Dda F; Romero TR; Duarte ID
Brain Res; 2014 May; 1562():69-75. PubMed ID: 24675031
[TBL] [Abstract][Full Text] [Related]
18. Thienorphine induces antinociception without dependence through activation of κ- and δ-, and partial activation of μ- opioid receptor.
Zhou P; Li Y; Yong Z; Chen M; Zhang Y; Su R; Gong Z
Brain Res; 2020 Dec; 1748():147083. PubMed ID: 32871137
[TBL] [Abstract][Full Text] [Related]
19. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
Lenard NR; Daniels DJ; Portoghese PS; Roerig SC
Eur J Pharmacol; 2007 Jul; 566(1-3):75-82. PubMed ID: 17383633
[TBL] [Abstract][Full Text] [Related]
20. Blockade of mu-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice.
Mizoguchi H; Hung KC; Leitermann R; Narita M; Nagase H; Suzuki T; Tseng LF
Eur J Pharmacol; 2003 Feb; 461(1):35-9. PubMed ID: 12568913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
